> ## Content Index > Fetch the complete content index at: https://bioweek.com/llms.txt > Use this file to discover other available public pages before exploring further. # Rasonque's Broad Label Is Built on Survival, Not Response - URL: https://bioweek.com/rasonques-broad-label-is-built-on-survival-not-response/ - Published: 2026-10-11T05:05:58.000Z - Updated: 2026-10-11T05:05:58.000Z - Description: The FDA's 321-page review of Rasonque documents the survival win that earned a broad pancreatic cancer label, and the mutation subgroups whose response data ran against the drug. - Author: BioWeek - Tags: Pipeline, Science Pancreatic cancer has been a graveyard of oncology drug development for two decades. On August 26, 2026, the FDA changed that when it [approved](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daraxonrasib-metastatic-pancreatic-adenocarcinoma?ref=bioweek.com) daraxonrasib (brand RASONQUE, Revolution Medicines), an inhibitor of the RAS GTPase family, for adults with metastatic pancreatic adenocarcinoma after prior systemic therapy, or who are not candidates for multiagent systemic therapy. The pivotal trial showed median overall survival of 13.2 months versus 6.7 months with physician's choice chemotherapy (hazard ratio 0.40, 95% CI 0.30 to 0.53), with response rates of 30% versus 11% and progression-free survival by blinded independent central review of 7.2 versus 3.6 months. More interesting is the breadth of the label, and the tension buried in the review behind it. ### One trial, two subgroups that ran against the drug The FDA's multi-disciplinary [review](https://www.accessdata.fda.gov/drugsatfda%5Fdocs/nda/2026/220910Orig1s000MultidisciplineR.pdf?ref=bioweek.com) (NDA 220910, 321 pages) records the survival win, and results a narrower approval might have treated as disqualifying. Only 16 patients (3%) in RASolute 302 had RAS wild-type tumors, and the subgroup's PFS result flipped sign depending on who measured it: a BICR-assessed hazard ratio of 1.92 (95% CI 0.39 to 9.52), numerically favoring chemotherapy, against an investigator-assessed 0.62 (95% CI 0.20 to 1.94) favoring daraxonrasib. The review states these inconsistent estimates reduce the reliability of the PFS results in that subgroup. The subgroup overall survival hazard ratio of 0.43 (0.09 to 1.98) was consistent with the overall result, though with 16 patients the interval spans nearly everything. The mutation-subtype breakdown raises similar questions. Exploratory response rates by KRAS subtype (review Table 11) were 50% for G12V versus 15% on chemotherapy, and 24% for G12D versus 10%. But the G12R subgroup, 12% of the trial population, responded at 7% on daraxonrasib versus 14% on chemotherapy. The drug lost to chemotherapy in that slice. ### Why the FDA chose breadth anyway The review's reasoning for a broad indication covering both mutant and wild-type RAS tumors rests on three legs. The subgroup overall survival result pointed in the same direction as the overall trial. The review cited the limited efficacy of chemotherapy in these groups, particularly the wild-type patients whose PFS estimate was unstable precisely because so few were enrolled. And it cited high unmet need. Daraxonrasib, an oral RAS(ON) multiselective tri-complex inhibitor that binds cyclophilin A and engages active, GTP-bound RAS, produces per the [publication](https://pubmed.ncbi.nlm.nih.gov/42223072/?ref=bioweek.com) in the New England Journal of Medicine active-state inhibition across mutant and wild-type RAS (KRAS, NRAS, HRAS). The mechanism argues for pan-RAS coverage: the drug was designed to inhibit wild-type RAS alongside mutants. Whether that translates into clinical benefit for the 3% without a detectable mutation is what the trial cannot firmly answer. ### The cost of breadth A broad label transfers subgroup uncertainty from the regulator to the clinic. Patients and clinicians will not know at the point of prescribing whether a tumor carries the biology that responded (G12V at 50%, G12D at 24%) or the one that did not (G12R at 7%). That one-in-eight subgroup's better outcome on chemotherapy received no mention in the indication. The label also covers patients not candidates for multiagent systemic therapy, a first-line population the pivotal trial never tested. ### Speed and conduct caveats The approval came fast. It ran under Real-Time Oncology Review and Assessment Aid, part of the Commissioner's National Priority Review Voucher pilot program, under Project Orbis with Health Canada (EMA and PMDA observing), about 6.5 months ahead of the goal date. An independent [commentary](https://academic.oup.com/oncolo/advance-article/doi/10.1093/oncolo/oyag346/8772457?ref=bioweek.com) in The Oncologist (August 28, 2026) adds a conduct caveat: 11.5% of control-arm patients withdrew before starting treatment and another 10.3% discontinued chemotherapy for reasons other than progression or toxicity, versus 0.4% and 3.6% on the experimental arm. In an open-label trial with no crossover, the commentary flags disappointment bias from this differential attrition, though it notes benefit appeared retained in the small groups without a detectable RAS mutation. ### Safety in context The tolerability profile is manageable by the trial's numbers. Dermatologic reactions occurred in 87% of daraxonrasib patients, gastrointestinal events in 67%, and stomatitis in 56%, mostly Grade 1 or 2, with treatment-related discontinuation at 2.9%. Two uncommon but serious risks carry label warnings: ILD/pneumonitis at 2.9% and gastrointestinal perforation or ulceration at 1.7%. Overall Grade 3-4 adverse events were less frequent with daraxonrasib than chemotherapy (60% versus 68%). ### What the first-line trials will decide Revolution Medicines began treating patients in Phase 3 RASolute 303 evaluating daraxonrasib as first-line treatment for metastatic pancreatic cancer, per the [announcement](https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-begins-treating-patients-phase-3-rasolute?ref=bioweek.com) of April 2, 2026\. A separate first-line trial, RASolute 305 (NCT07621718), tests the G12D-selective inhibitor zoldonrasib plus chemotherapy versus placebo plus chemotherapy in metastatic KRAS G12D-mutated pancreatic adenocarcinoma. The two programs amount to a head-to-head test of philosophies by the same company: pan-RAS breadth or allele-specific precision, in the setting where most patients are treated. RAS mutations drive more than 90% of pancreatic ductal adenocarcinomas, so the stakes cover nearly the entire disease. The broad label built on the 13.2-month survival result is defensible on its own terms. Whether it holds up outside the trial, mutation by mutation, is the open question.